Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

By D. Kirpotin, D. Drummond, Y. Shao, M. Shalaby, K. Hong, Ulrik B. Nielsen, J. Marks, C. Benz, John W. Park. Cancer Research, 2006

1,079 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7a6bfb1e597b4a2b1d1ea30a5ab03eea219c8660

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Jun Wu
2. O. Farokhzad
3. N. Bertrand
4. N. Kamaly
5. Xiaoyang Xu
6. F. Danhier
7. Robert Langer
8. V. Préat

In Molecular Biology

1. Jun Wu
2. O. Farokhzad
3. N. Bertrand
4. N. Kamaly
5. Xiaoyang Xu
6. Robert Langer
7. F. Danhier
8. S. Hua

In Radiology, Nuclear Medicine and Imaging

1. N. Bertrand
2. Theresa M. Allen
3. P. Cullis

Citations in the corpus

• Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. (2019, background): “tary cell surface receptors on targeted cells [28].”
• PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “This is the base of the design of delivery systems targeted to endocytosis-prone surface receptors [95].”
• Basics and recent advances in peptide and protein drug delivery (2013, positive): “One study by Kirpotin and colleagues demonstrated that monoclonal antibodies (MAb) directed against Her2/neu increased the cytoplasmic delivery of the liposomes contents [224].”
• Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems (2018, neutral): “Different types of lipidic nanocarriers have been applied as drug delivery systems for diagnostic and targeted nanotherapy (employing active or passive targeting mechanisms) to achieve the maximum cellular uptake and therapeutic index [2,16,17].”
• Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “This is in line with the finding that the overall tumor accumulation of a nanomedicine formulation generally does not improve upon active targeting, while its intratumoral distribution may benefit, as a result of more target cell uptake and less macrophage uptake [216,217].”
• Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles (2009, background): “(12) and our previous observations from the targeted delivery of siRNA (13).”
• A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “For instance, HER2 specific antibody (Trastuzumab® or Herceptin®) modified nanoparticles were able to localize and deliver the therapeutic payload specifically in HER2 expressing tumor cells [35].”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “improved anti-tumor effect, by enhancing intracellular drug delivery to HER2-overexpressing cancer cells (Kirpotin et al., 2006).”
• Liposomal drug delivery systems: from concept to clinical applications. (2013, background): “containing entrapped drug, by the target cells [129].”